65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis

Acne Vulgaris: Pathophysiology & Lesion Morphology

Acne vulgaris is a chronic inflammatory disorder of the pilosebaceous unit, affecting over 85% of adolescents and young adults, with a growing prevalence among adult females. The disease process is orchestrated by four interconnected, interdependent pathogenic factors that dictate both clinical lesion morphology and pharmacotherapeutic selection.

The Four Interconnected Pathogenic Pillars

1. Follicular Hyperkeratinization & Microcomedone Formation: Abnormal hyperproliferation and cohesive desquamation of keratinocytes lining the infundibulum of the pilosebaceous follicle lead to retention of stratum corneum cells. This micro-obstruction traps lipids and cellular debris, forming the microscopic precursor of all acne lesions: the microcomedone.
2. Androgen-Mediated Sebum Overproduction: During adrenarche and puberty, circulating and locally synthesized androgens (primarily dihydrotestosterone [DHT] and dehydroepiandrosterone sulfate [DHEA-S]) bind nuclear androgen receptors on sebocytes. This stimulates marked sebaceous gland hypertrophy and excessive sebum production. Sebum serves as a high-lipid nutrient substrate and alters follicular oxygen tension.
3. Follicular Proliferation of Cutibacterium acnes: The anaerobically plugged, sebum-rich infundibulum provides an ideal ecological niche for the proliferation of Cutibacterium acnes (formerly Propionibacterium acnes), an anaerobic, Gram-positive aerotolerant diphtheroid rod that constitutes part of the normal cutaneous microbiome.
4. Perifollicular Inflammation & Immune Activation: C. acnes hydrolyzes sebum triglycerides into free fatty acids via bacterial lipases. These free fatty acids irritate follicular epithelium. Crucially, C. acnes activates Toll-like receptor 2 (TLR-2) on local monocytes, perifollicular macrophages, and dendritic cells, triggering the transcription factor nuclear factor-kappa B (NF-κB) and the massive release of pro-inflammatory cytokines (interleukin-1α [IL-1α], IL-8, IL-12, and tumor necrosis factor-alpha [TNF-α]). Neutrophils migrate into the follicle, release hydrolytic enzymes, and cause follicular wall thinning and rupture, extruding keratin, lipids, and bacterial antigens into the surrounding dermis and provoking an acute foreign-body inflammatory reaction.

                    THE 4-STEP PATHOGENIC CASCADE OF ACNE VULGARIS

   [Excess Androgens]       [Altered Desquamation]       [Bacterial Overgrowth]       [Immune Activation]
         │                         │                            │                           │
         ▼                         ▼                            ▼                           ▼
   Sebaceous Gland ───► Follicular Obstruction ───► Cutibacterium acnes ───► TLR-2 / NF-κB Pathway
     Hyperplasia          & Microcomedone               Proliferation          Pro-inflammatory Cascade
         │                         │                            │                           │
         └─────────────────────────┴────────────────────────────┴───────────────────────────┘
                                                   │
                                                   ▼
                                   CLINICAL ACNE LESION SPECTRUM
                       [Non-inflammatory Comedones ──► Inflammatory Papules/Cysts]

Lesion Morphology & Classification

Clinical lesions are divided into non-inflammatory and inflammatory categories:

• Non-Inflammatory Lesions (Comedones):
  • Open Comedones ("Blackheads"): Follicular orifices are visibly dilated, plugged with a compact keratin-lipid mass. The dark black coloration is not dirt; rather, it is caused by the oxidation of melanin and oxidized lipids when exposed to atmospheric air.
  • Closed Comedones ("Whiteheads"): Tiny, 1- to 2-mm, smooth, flesh-colored to whitish dome-shaped papules without an apparent follicular opening. The keratin plug remains beneath the closed epidermal surface, creating an enclosed anaerobic environment prone to inflammatory rupture.
• Inflammatory Lesions:
  • Papules: Small (<5 mm), erythematous, tender, elevated dome-shaped lesions indicating superficial dermal inflammation around a disrupted follicle.
  • Pustules: Circumscribed, elevated superficial lesions containing visible whitish-yellow purulent exudate (dead neutrophils and necrotic debris).
  • Nodules: Deep-seated, firm, painful inflammatory lesions (>5 mm) that extend deep into the dermis and subcutis; indicative of extensive follicular wall rupture.
  • Cysts: Large, fluctuant, suppurative pseudocysts resulting from coalescent ruptured nodules; carry an extremely high propensity for permanent scarring (ice-pick, rolling, or boxcar atrophic scars, or hypertrophic keloidal scars).

---

Evidence-Based Stepwise Management (AAD 2024 Guidelines)

The American Academy of Dermatology (AAD) updated clinical practice guidelines stratify management by clinical morphology, severity, and patient-specific factors. Treatment must target as many pathogenic mechanisms simultaneously as possible.

                   EVIDENCE-BASED TREATMENT LADDER FOR ACNE VULGARIS (AAD 2024)

   Severity / Type           First-Line Medical Regimens                       Key Counseling & Clinical Pearls
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Mild Comedonal            Topical Retinoid Monotherapy                      Apply at night to dry skin (pea-sized);
                             • Adapalene 0.1% or 0.3% gel/cream                normalizes keratinocyte desquamation;
                             • Tretinoin 0.025%–0.1% cream/gel                 warn about initial "retinoid purge",
                             • Tazarotene 0.05%–0.1% cream/gel                 erythema, and obligatory photosensitivity.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────────
   Mild Inflammatory /       Topical Retinoid + Benzoyl Peroxide (BPO) 2.5–5%   BPO generates reactive oxygen species with
   Papulopustular            ± Topical Clindamycin 1% solution/gel             ZERO bacterial resistance; NEVER PRESCRIBE
                             (Prefer fixed-dose combination formulations)      TOPICAL ANTIBIOTIC MONOTHERAPY.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────────
   Moderate Inflammatory     Topical Retinoid + BPO 2.5–5% + Oral Antibiotic   Doxycycline 100 mg daily first-line;
                             • First-line: Doxycycline 100 mg daily            HARD CEILING: LIMIT ORAL ANTIBIOTICS
                             • Alternative: Minocycline 50–100 mg BID          TO 3–4 MONTHS; pill esophagitis counseling.
                             • Female hormonal therapy adjunct (COC/Spirono)   Take with full glass of water, stay upright.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────────
   Severe Nodulocystic /     Oral Isotretinoin Monotherapy                     Cumulative goal: 120–150 mg/kg;
   Scarring / Refractory     • 0.5–1.0 mg/kg/day divided BID for 4–6 months    Mandatory iPLEDGE REMS program compliance;
                             (Targets all 4 pathogenic mechanisms!)            two forms of contraception; monthly LFTs,
                                                                               lipid panel, and pregnancy testing.
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════════

1. Topical Retinoids: The Foundational Bedrock

Topical retinoids bind specific nuclear retinoic acid receptors (RAR-β and RAR-γ), directly normalizing follicular desquamation, accelerating cell turnover, expelling mature comedones, and preventing new microcomedone formation. In addition, retinoids exert indirect anti-inflammatory actions by downregulating TLR-2 expression.

• Agents:
  • Adapalene (0.1% OTC, 0.3% Rx): Synthetic third-generation naphthoic acid derivative; RAR-β/γ selective. Possesses the highest tolerability profile with the lowest incidence of cutaneous irritation. Photostable, allowing daytime application, and chemically compatible with concomitant benzoyl peroxide.
  • Tretinoin (0.025%, 0.05%, 0.1%): All-trans retinoic acid. Highly effective but degraded by light; must be applied strictly at bedtime. Inactivated by direct contact with benzoyl peroxide (must apply at opposite times of day if used uncombined).
  • Tazarotene (0.05%, 0.1%): Receptor-selective prodrug; highly potent but exhibits higher rates of localized erythema and peeling. Pregnancy Category X (contraindicated in pregnancy).
  • Trifarotene (0.005%): Fourth-generation RAR-γ selective agonist approved for facial and truncal acne.
• Patient Counseling Pearl: Apply once daily at bedtime to clean, completely dry skin (waiting 15–20 minutes after washing to reduce stinging). Use a single pea-sized amount distributed across the entire face—not as spot treatment. Anticipate a transient "retinoid dermatitis" (scaling, erythema, dryness) and mild "purging" during the first 2–4 weeks. Daily broad-spectrum SPF ≥30 sunscreen is non-negotiable.

2. Benzoyl Peroxide (BPO): The Resistance-Free Antimicrobial

Benzoyl peroxide is a lipophilic oxidizing agent that readily penetrates the sebum-rich follicular canal. Once inside, it generates reactive oxygen species (ROS / free radicals), rapidly lysing bacterial cell walls and oxidatively destroying C. acnes proteins.

• Zero Resistance: Because its mechanism is physical oxidation rather than target-site receptor binding, there is zero documented bacterial resistance to benzoyl peroxide worldwide, even after decades of continuous clinical use.
• Concentration Equivalence: Controlled clinical trials prove that 2.5% or 5% BPO formulations are clinically equivalent in bactericidal efficacy to 10% formulations, but produce markedly less cutaneous irritation, scaling, and contact dermatitis.
• Counseling: Warn patients that BPO oxidizes and bleaches colored towels, pillowcases, and clothing.

3. Topical Antibiotics: The Cardinal Prohibition Rule

• Topical Clindamycin 1% and Erythromycin 2% inhibit the bacterial 50S ribosomal subunit, reducing C. acnes colony counts and dampening neutrophil chemotaxis.

• [!CRITICAL] Never Use Topical Antibiotic Monotherapy Monotherapy with topical clindamycin or erythromycin leads to the rapid selection of macrolide/lincosamide-resistant C. acnes strains within 4 to 8 weeks, rendering therapy completely ineffective and promoting widespread cross-resistance. Topical antibiotics must ALWAYS be combined with benzoyl peroxide (either as fixed-dose combination gels—e.g., clindamycin 1%/BPO 5%—or applied concomitantly).

4. Oral Antibiotics for Moderate-to-Severe Inflammatory Acne

Oral antibiotics are reserved for widespread inflammatory acne (face, chest, back) failing comprehensive topical regimens.

• First-Line Agents: Second-generation tetracyclines:
  • Doxycycline: 100 mg orally once daily (or 50–100 mg BID).
  • Minocycline: 50–100 mg orally BID (or weight-based extended-release formulation).
  • Sarecycline: Narrow-spectrum tetracycline targeting C. acnes with low enteric Gram-negative disruption.
• Mechanism: Reversibly bind the 30S ribosomal subunit. Crucially, tetracyclines possess powerful intrinsic non-antibiotic anti-inflammatory properties: they inhibit matrix metalloproteinases (MMP-8, MMP-9), suppress neutrophil chemotaxis, and downregulate pro-inflammatory cytokines.
• Treatment Duration Cap: The AAD strictly mandates that oral antibiotics be limited to a maximum duration of 3 to 4 months. They must always be co-prescribed with a topical retinoid and benzoyl peroxide. Once inflammatory lesions regress, oral antibiotics should be systematically tapered and discontinued, transitioning the patient to topical retinoid + BPO maintenance therapy.
• Adverse Effects & Critical Warnings:
  • Pill-Induced Esophagitis: Doxycycline produces direct corrosive chemical ulceration if lodged in the esophagus. Patients must take tablets with a full 8-ounce glass of water and remain strictly upright for at least 30 minutes before lying down.
  • Phototoxicity: Exaggerated sunburn reactions upon UV exposure.
  • Vestibular Toxicity & Hyperpigmentation: Minocycline can cause dose-dependent vertigo, dizziness, and blue-gray slate pigmentation of skin, sclera, gums, and scars. Rare risks include drug-induced lupus and DRESS syndrome.
  • Contraindications: Contraindicated in pregnancy and in children under 8 years of age due to permanent tooth discoloration (yellow-gray-brown dentin staining) and reversible suppression of long bone growth.

5. Oral Isotretinoin (Accutane): The Curative Systemic Retinoid

Oral isotretinoin (13-cis-retinoic acid) is the most potent anti-acne medication known, capable of inducing permanent long-term clinical remission.

• Targeting All Four Mechanisms: Isotretinoin is the only single agent that simultaneously shuts down all four pathogenic pillars: 1) induces profound sebocyte apoptosis, reducing sebaceous gland size by up to 90% and sebum production by >80%; 2) normalizes infundibular desquamation, eliminating comedogenesis; 3) profoundly deprives C. acnes of its lipid nutrient substrate; and 4) exerts direct anti-inflammatory immunomodulatory actions.
• Indications: Severe, scarring nodulocystic acne; moderate inflammatory acne refractory to oral antibiotics; rapidly scarring acne; or severe acne causing profound psychosocial depression/dysmorphia.
• Dosing Protocol: Initiated at 0.5 mg/kg/day for month 1, then escalated to 1.0 mg/kg/day divided twice daily with meals containing high dietary fats (absorption is lipid-dependent). Treatment is continued until achieving a cumulative target dose of 120 to 150 mg/kg (typically over 20 to 24 weeks). Achieving this cumulative threshold minimizes the long-term relapse rate.
• The iPLEDGE REMS Program:
  • Isotretinoin is a devastating human teratogen (Embryofetopathy), causing severe microtia/anotia, micrognathia, cleft palate, conotruncal cardiac defects, hydrocephalus, and intellectual disability in over 30% of exposed fetuses.
  • The iPLEDGE Mandate: Female patients of childbearing potential must have two negative serum or urine pregnancy tests documented prior to initiation. They must commit to using two independent, effective forms of contraception (or practice continuous, documented complete abstinence) starting 1 month before treatment, throughout the entire treatment course, and for at least 1 full month following complete cessation.
  • Monthly negative pregnancy tests must be logged into the national registry within a strict 7-day prescription window before each refill is dispensed.
• Laboratory Monitoring Protocol:
  • Baseline: Fasting lipid panel (triglycerides, total cholesterol, HDL), comprehensive metabolic panel (AST, ALT), and complete blood count (CBC).
  • Follow-up: Repeat fasting lipids and liver transaminases at 1 month, and periodically thereafter until stable. Modest triglyceride elevations (up to 300–400 mg/dL) and mild transaminitis are common; if serum triglycerides exceed 800 mg/dL, isotretinoin must be dose-reduced or halted to prevent acute pancreatitis.
• Common Adverse Effects:
  • Mucocutaneous (100%): Cheilitis (severe dry, cracked lips is the universal clinical marker of therapeutic compliance), xerosis, epistaxis (nasal vestibulitis), conjunctivitis/dry eyes (contact lens intolerance), brittle nails, and skin fragility.
  • Musculoskeletal: Arthralgias, back pain, myalgias, elevated serum creatine kinase (CK) following vigorous exercise.
  • Neuropsychiatric: Active monitoring for depression, suicidal ideation, and mood changes is recommended, although large epidemiological studies have not established a direct causal link.

6. Hormonal Therapies for Adult Females

In adult women with persistent lower-face (jawline and chin) inflammatory papules that flare premenstrually, systemic hormonal manipulation provides superior long-term disease control:

1. Combined Oral Contraceptives (COCs): FDA-approved formulations containing ethinyl estradiol paired with low-androgenic progestins (norgestimate, norethindrone) or an anti-androgenic progestin (drospirenone, a spironolactone analogue). Estrogen increases hepatic synthesis of sex hormone-binding globulin (SHBG), binding free circulating testosterone, while suppressing pituitary LH secretion to dampen ovarian androgen output.
2. Spironolactone: Aldosterone antagonist that competitively blocks peripheral androgen receptors on sebocytes and inhibits 5-alpha-reductase. Dosed at 50 to 100 mg orally once daily (or divided BID). Reduces sebum excretion by 30–50%. Side effects include menstrual irregularities (addressed by combining with a COC), breast tenderness, lightheadedness, and hyperkalemia. In healthy young women without renal impairment, routine serum potassium monitoring is no longer mandatory, but baseline and periodic checks are prudent in older patients or those taking ACE inhibitors/ARBs. Strict contraindication in pregnancy due to the risk of feminization of a male fetus.

---

Rosacea: Clinical Subtypes, Diagnosis & Therapeutics

Rosacea is a chronic vascular and neuroinflammatory disorder localized primarily to the convexities of the central face (cheeks, nose, chin, and forehead). It predominantly affects fair-skinned individuals of Celtic or Northern European descent, with peak onset between ages 30 and 50.

Pathophysiology

Rosacea involves neurovascular dysregulation, an exaggerated innate immune response, and microbial trigger factors:

• Neurovascular Dysregulation: TRP (transient receptor potential) ion channels on sensory cutaneous nerve endings are hypersensitive, driving intense facial flushing, persistent vasodilation, and burning pain in response to thermal, chemical, or emotional triggers.
• Innate Immune Activation: Patients overexpress the antimicrobial peptide cathelicidin (LL-37), which is cleaved into aberrant vasoactive and pro-inflammatory fragments by elevated stratum corneum kallikrein-5 protease.
• Microbiome Overgrowth: Microscopic Demodex folliculorum mites reside in massive excess within the sebaceous follicles, serving as antigenic targets that trigger T-cell and toll-like receptor activation.

                         THE FOUR DISTINCT SUBTYPES OF ROSACEA

   Subtype                 Key Clinical Features                             First-Line Evidence-Based Management
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════
   1. Erythematotelan-     Persistent centrofacial erythema; recurrent       • Strict trigger avoidance (spicy, hot liquids, EtOH)
      giectatic (ETR)      flushing (> 10 min); prominent telangiectasias;   • Daily physical mineral sunscreen (SPF ≥ 30)
                           burning, stinging; sensitive "reactive" skin.      • Topical Brimonidine 0.33% gel / Oxymetazoline 1%
                                                                             • Pulsed Dye Laser (PDL) for fixed telangiectasias.
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   2. Papulopustular       Confluent erythema with dome-shaped inflammatory  • Topical Metronidazole 0.75%–1% gel/cream
                           papules and tiny pustules across central face;    • Topical Ivermectin 1% cream (kills Demodex!)
                           CARDINAL RULE: COMPLETE ABSENCE OF COMEDONES.     • Topical Azelaic Acid 15% gel or foam
                                                                             • Oral Doxycycline 40 mg subantimicrobial daily.
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   3. Phymatous            Marked sebaceous hyperplasia, follicular dilation, • Early: Oral isotretinoin to shrink sebaceous bulk
                           dermal edema, and fibrous tissue hypertrophy;     • Advanced: Electrosurgical debulking, carbon
                           RHINOPHYMA: bulbous, lobulated, purplish nose.      dioxide (CO2) laser resurfacing, or cold-blade
                           Occurs almost exclusively in adult males.           tangential surgical excision.
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   4. Ocular Rosacea       Occurs in > 50% of rosacea patients; blepharitis, • Eyelid hygiene (warm compresses, baby shampoo)
                           conjunctival injection, foreign-body "gritty"     • Preservative-free artificial tears
                           sensation, photophobia, telangiectasia of lid     • Topical cyclosporine ophthalmic drops
                           margin, recurrent chalazia and styes.             • Oral Doxycycline 40–100 mg daily for 6–12 weeks.
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════

The Cardinal Board Exam Diagnostic Rule

[!IMPORTANT] The Presence vs. Absence of Comedones The definitive, high-yield clinical differentiator between acne vulgaris and papulopustular rosacea is that rosacea NEVER features comedones (no blackheads, no whiteheads). If a patient with central facial papules and pustules has open or closed comedones, the diagnosis is acne vulgaris. If comedones are entirely absent and accompanied by flushing and telangiectasias, the diagnosis is rosacea.

Therapeutic Specifics for Rosacea

1. Trigger Avoidance & Sun Protection: Elimination of personal triggers: hot beverages, alcohol (especially red wine), spicy capsaicin-containing foods, thermal extremes (saunas, cold wind), and emotional stress. Broad-spectrum physical sunscreens containing micronized zinc oxide or titanium dioxide (SPF ≥30) must be worn daily.
2. Topical Brimonidine 0.33% Gel & Oxymetazoline 1% Cream: Highly selective alpha-2 and alpha-1 adrenergic receptor agonists, respectively. They cause direct vasoconstriction of dilated cutaneous facial arterioles, providing temporary (8–12 hour) clearing of erythema. Caution: Brimonidine carries a risk of paradoxically severe "rebound flushing" upon wearing off in up to 15% of patients.
3. Topical Ivermectin 1% Cream: A broad-spectrum anti-parasitic agent that directly eradicates Demodex folliculorum mites while exerting potent anti-inflammatory properties (inhibits NF-κB and lipopolysaccharide-induced inflammatory cytokines). Demonstrates superior clinical clearance over metronidazole 0.75% in head-to-head randomized trials.
4. Subantimicrobial Anti-inflammatory Dose Doxycycline: Dosed at 40 mg orally once daily (administered as 30 mg immediate-release and 10 mg delayed-release beads). At this low concentration, doxycycline falls below the minimum inhibitory concentration (MIC) required to exert antimicrobial pressure on bacteria, completely avoiding the development of bacterial resistance or vaginal candidiasis. Instead, it powerfully suppresses neutrophil chemotaxis, downregulates cathelicidin LL-37 processing, and inhibits matrix metalloproteinases.
5. Topical Corticosteroid Contraindication: Fluorinated topical corticosteroids applied to the central face cause temporary improvement followed by catastrophic steroid-induced rosacea, accompanied by epidermal atrophy, profound telangiectasias, and severe pustular rebound eruptions upon withdrawal.

---

Seborrheic Dermatitis: Clinical Spectrum & Management

Seborrheic dermatitis is an extremely common, chronic, relapsing, superficial inflammatory dermatosis that manifests as greasy, yellowish, micaceous or flaky scales overlying patches of poorly demarcated erythema. It exhibits a predilection for anatomic areas with high concentrations of active sebaceous glands.

Etiopathogenesis: The Malassezia Nexus

The pathogenesis centers on an abnormal host immune response to lipophilic yeasts of the genus Malassezia (Malassezia globosa and Malassezia restricta), which reside naturally within sebum-rich hair follicles. Malassezia produces lipases that metabolize sebaceous triglycerides into free fatty acids (oleic and arachidonic acid). These unsaturated fatty acids penetrate the stratum corneum, disrupt the epidermal barrier, and stimulate keratinocyte cytokine release and localized cell-mediated immune inflammation in genetically susceptible individuals.

                   ANATOMIC DISTRIBUTION OF SEBORRHEIC DERMATITIS

   Anatomic Site           Typical Clinical Findings
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Scalp                   From diffuse, fine, white-to-gray scaling without erythema ("Dandruff" / Pityriasis
                           capitis) to prominent erythematous plaques with thick, greasy, adherent yellowish crusts.
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   Central Face            Erythema and greasy salmon-pink scaling concentrated along the nasolabial folds,
                           glabella, medial eyebrows, and hairline borders (corona seborrheica).
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   Ears & Canals           Retroauricular creases (often fissured and painful), external auditory canals,
                           and the concha bowl; frequent cause of persistent external otitis.
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   Trunk & Intertriginous  Presternal midline anterior chest (petaloid or circinate greasy patches), interscapular
                           upper back, axillae, inframammary creases, and umbilicus.
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════

Clinical Variants & High-Yield Systemic Associations

1. Infantile Seborrheic Dermatitis ("Cradle Cap"):
   • Arises within the first 2 to 10 weeks of life due to transplacental transfer of maternal androgens stimulating infant sebaceous glands.
   • Manifests as thick, tenacious, greasy, yellowish-brown crusts and scales over the vertex of the scalp. Lesions may spread to the face, retroauricular folds, and diaper region.
   • Benign & Self-Limiting: The infant is asymptomatic (does not scratch; non-pruritic). It resolves spontaneously by 6 to 12 months of age.
   • Management: Reassurance; conservative measures include applying warm mineral oil, baby oil, or petrolatum to the scalp to soften crusts for 20 minutes, followed by gentle mechanical desquamation with a soft-bristled baby toothbrush and washing with a mild baby shampoo. For persistent inflammation, a low-potency topical steroid (hydrocortisone 1% cream) can be applied for several days.
2. High-Yield Adult Systemic Associations:

   • [!CRITICAL] Severe Seborrheic Dermatitis as a Marker for HIV & Parkinson Disease

     1. HIV Infection: While mild seborrheic dermatitis occurs in 3–5% of the general population, it occurs in up to 85% of individuals with advanced HIV/AIDS. An explosive, sudden-onset, widespread, fiery-red, treatment-refractory seborrheic dermatitis involving the entire face, neck, and trunk is a classic early clinical harbinger of acute HIV seroconversion or progressing immunosuppression (CD4 count <400/μL). Mandatory Board Rule: Any young or middle-aged adult presenting with sudden, extensive, recalcitrant seborrheic dermatitis must be screened with a fourth-generation HIV-1/2 antigen/antibody immunoassay.
     2. Parkinson Disease & Neurodegenerative Disorders: Seborrheic dermatitis exhibits an extraordinary prevalence in Parkinson disease. Autonomic nervous system dysfunction induces excessive sebum production ("seborrhea") and pooling, coupled with immobility of facial expression (the parkinsonian "masked facies"), creating a fertile environment for Malassezia overgrowth.

Longitudinal Management Strategy

Because seborrheic dermatitis is a chronic condition with an intrinsic genetic and microbial basis, the therapeutic goal is symptom control and maintenance, not permanent eradication.

• Scalp Disease (Adult Dandruff & Plaque Disease):
  • Medicated Antifungal Shampoos: Ketoconazole 2% shampoo, Selenium sulfide 2.5%, or Zinc pyrithione 1–2%. Patients must lather the shampoo into the scalp and leave it in place for 5 to 10 minutes before rinsing to ensure adequate fungicidal tissue penetration. Use 2 to 3 times weekly.
  • Topical Corticosteroid Solutions/Foams: For acute intense pruritus and erythema, mid-potency topical corticosteroids (fluocinolone acetonide 0.01% scalp oil or clobetasol 0.05% shampoo used twice weekly) provide rapid symptomatic relief during flares.
• Facial and Delicate Skin Folds:
  • Topical Antifungals: Ketoconazole 2% cream or ciclopirox 0.77% cream applied once to twice daily is the first-line maintenance therapy of choice, directly suppressing Malassezia load without skin-thinning side effects.
  • Low-Potency Topical Corticosteroids: Hydrocortisone 1% cream or desonide 0.05% cream applied BID for brief bursts (3–5 days) to rapidly extinguish active inflammation.
  • Steroid-Sparing Topical Calcineurin Inhibitors: Pimecrolimus 1% cream or tacrolimus 0.03%–0.1% ointment are outstanding off-label steroid-sparing maintenance options for sensitive facial, eyelid, and nasolabial folds. They suppress T-cell NFAT transcription without inducing skin atrophy, telangiectasias, or perioral dermatitis.